Advances in breast cancer therapy in the age of molecular diagnostics

The treatment of breast cancer has undergone a profound transformation over the last two decades. While clinical-pathological parameters long formed the sole basis for therapy decisions, molecular diagnostics and personalized therapy concepts are increasingly determining treatment today. Multigenomic signatures, next-generation sequencing and liquid biopsy have redefined risk stratification. At the same time, targeted drugs have been developed that intervene precisely in oncogenic signaling pathways. In addition, antibody-drug conjugates and immune checkpoint inhibitors are expanding the therapeutic spectrum.